These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34895291)

  • 1. Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial).
    Minelli A; Barlati S; Vitali E; Bignotti S; Dattilo V; Tura GB; Maffioletti E; Giacopuzzi E; Santoro V; Perusi G; Cobelli C; Magri C; Bonizzato S; Bocchio-Chiavetto L; Spina E; Vita A; Gennarelli M
    Trials; 2021 Dec; 22(1):896. PubMed ID: 34895291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.
    Saya S; Chondros P; Abela A; Mihalopolous C; Chatterton ML; Gunn J; Chen TF; Polasek TM; Dettmann E; Brooks R; King M; Spencer L; Alphonse P; Milton S; Ramsay G; Siviour Z; Liew J; Ly P; Thoenig M; Seychell R; La Rocca F; Hesson LB; Mejias N; Sivertsen T; Galea MA; Bousman C; Emery J
    Trials; 2023 May; 24(1):342. PubMed ID: 37208772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
    Stäuble CK; Lampert ML; Allemann S; Hatzinger M; Hersberger KE; Meyer Zu Schwabedissen HE; Imboden C; Mikoteit T
    Trials; 2021 Dec; 22(1):919. PubMed ID: 34906208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
    Oslin DW; Lynch KG; Shih MC; Ingram EP; Wray LO; Chapman SR; Kranzler HR; Gelernter J; Pyne JM; Stone A; DuVall SL; Lehmann LS; Thase ME; ; Aslam M; Batki SL; Bjork JM; Blow FC; Brenner LA; Chen P; Desai S; Dieperink EW; Fears SC; Fuller MA; Goodman CS; Graham DP; Haas GL; Hamner MB; Helstrom AW; Hurley RA; Icardi MS; Jurjus GJ; Kilbourne AM; Kreyenbuhl J; Lache DJ; Lieske SP; Lynch JA; Meyer LJ; Montalvo C; Muralidhar S; Ostacher MJ; Paschall GY; Pfeiffer PN; Prieto S; Przygodzki RM; Ranganathan M; Rodriguez-Suarez MM; Roggenkamp H; Schichman SA; Schneeweis JS; Simonetti JA; Steinhauer SR; Suppes T; Umbert MA; Vassy JL; Voora D; Wiechers IR; Wood AE
    JAMA; 2022 Jul; 328(2):151-161. PubMed ID: 35819423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
    Thase ME; Parikh SV; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Jablonski MR; Greden JF
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31721487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
    McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
    J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder.
    Perlis RH; Dowd D; Fava M; Lencz T; Krause DS
    Depress Anxiety; 2020 Sep; 37(9):834-841. PubMed ID: 32383277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
    Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Shelton RC; Macaluso M; Li J; Traxler P; Logan J; Brown L; Dechairo B; Greden JF
    Am J Geriatr Psychiatry; 2020 Sep; 28(9):933-945. PubMed ID: 32513518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.
    Tiwari AK; Zai CC; Altar CA; Tanner JA; Davies PE; Traxler P; Li J; Cogan ES; Kucera MT; Gugila A; Braganza N; Emmerson H; Zai G; Müller DJ; Levitan R; Kloiber S; Daskalakis ZJ; Frey BN; Bowen JM; Tarride JE; Tytus R; Chandrasena R; Voudouris N; Taylor VH; Tempier R; Sharma V; Vasudev A; Dzongowski P; Pliamm L; Greenspoon T; Dechairo BM; Kennedy JL
    Transl Psychiatry; 2022 Mar; 12(1):101. PubMed ID: 35288545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial.
    Maier HB; Neyazi A; Bundies GL; Meyer-Bockenkamp F; Bleich S; Pathak H; Ziert Y; Neuhaus B; Müller FJ; Pollmann I; Illig T; Mücke S; Müller M; Möller BK; Oeltze-Jafra S; Kacprowski T; Voges J; Müntefering F; Scheiber J; Reif A; Aichholzer M; Reif-Leonhard C; Schmidt-Kassow M; Hegerl U; Reich H; Unterecker S; Weber H; Deckert J; Bössel-Debbert N; Grabe HJ; Lucht M; Frieling H
    Trials; 2024 Apr; 25(1):247. PubMed ID: 38594753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.
    Vande Voort JL; Orth SS; Shekunov J; Romanowicz M; Geske JR; Ward JA; Leibman NI; Frye MA; Croarkin PE
    J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):46-55. PubMed ID: 34099307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Neurostimulation of the Brain in Depression Trial: Protocol for a Randomized Controlled Trial of Transcranial Direct Current Stimulation in Treatment-Resistant Depression.
    Suleman R; Tucker BV; Dursun SM; Demas ML
    JMIR Res Protoc; 2021 Mar; 10(3):e22805. PubMed ID: 33729165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
    Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
    J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study.
    Ramsey CM; Lynch KG; Thase ME; Gelernter J; Kranzler HR; Pyne JM; Shih MC; Stone A; ; Oslin DW
    J Affect Disord; 2021 Mar; 282():1272-1277. PubMed ID: 33601706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study).
    Rubio-Valera M; Beneitez I; Peñarrubia-María MT; Luciano JV; Mendive JM; McCrone P; Knapp M; Sabés-Figuera R; Kocyan K; García-Campayo J; Serrano-Blanco A
    BMC Psychiatry; 2015 Mar; 15():63. PubMed ID: 25885818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.
    Islam F; Gorbovskaya I; Müller DJ
    Adv Exp Med Biol; 2021; 1305():231-255. PubMed ID: 33834403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists.
    Tanner JA; Davies PE; Voudouris NC; Shahmirian A; Herbert D; Braganza N; Gugila A; Dechairo BM; Kennedy JL
    J Psychiatr Res; 2018 Sep; 104():157-162. PubMed ID: 30081389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.
    Oedegaard KJ; Alda M; Anand A; Andreassen OA; Balaraman Y; Berrettini WH; Bhattacharjee A; Brennand KJ; Burdick KE; Calabrese JR; Calkin CV; Claasen A; Coryell WH; Craig D; DeModena A; Frye M; Gage FH; Gao K; Garnham J; Gershon E; Jakobsen P; Leckband SG; McCarthy MJ; McInnis MG; Maihofer AX; Mertens J; Morken G; Nievergelt CM; Nurnberger J; Pham S; Schoeyen H; Shekhtman T; Shilling PD; Szelinger S; Tarwater B; Yao J; Zandi PP; Kelsoe JR
    BMC Psychiatry; 2016 May; 16():129. PubMed ID: 27150464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.